Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS) Topline Phase 2 data from both the AD

The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarterWATERTOWN, Mass., Oct. 27, 2023 (GLOBE N

Recently, Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of the IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023. This news further confirms the s

In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile Clinical endpoints addressing disease burden and symptoms demonstrate a highly competitive profile after four weeks of dosing, with substantial responses in majority of both HS and AD patients Modest, non-adverse QTc prolongation spontaneously resolves back to baseline during the 4-week dosing period Sanofi has committed to advance KT-474 (SAR444656) into Phase 2 clinical trials

Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalationKT-253 has completed IND enabling studiesWATERTOWN, Mass., Oct. 13, 2022 (GLO